コンテンツへスキップ
Merck

B1158000

ブメタニド

European Pharmacopoeia (EP) Reference Standard

別名:

3-(アミノスルホニル)-5-(ブチルアミノ)-4-フェノキシ安息香酸

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C17H20N2O5S
CAS番号:
分子量:
364.42
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

グレード

pharmaceutical primary standard

APIファミリー

bumetanide

メーカー/製品名

EDQM

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

SMILES記法

CCCCNc1cc(cc(c1Oc2ccccc2)S(N)(=O)=O)C(O)=O

InChI

1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)

InChI Key

MAEIEVLCKWDQJH-UHFFFAOYSA-N

遺伝子情報

human ... SLC12A1(6557)

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Bumetanide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

その他情報

Sales restrictions may apply.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


Choose from one of the most recent versions:

試験成績書(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Kristopher T Kahle et al.
Neurosurgical focus, 25(3), E22-E22 (2008-09-02)
Seizures that occur during the neonatal period do so with a greater frequency than at any other age, have profound consequences for cognitive and motor development, and are difficult to treat with the existing series of antiepileptic drugs. During development
A Ward et al.
Drugs, 28(5), 426-464 (1984-11-01)
Bumetanide is a potent 'loop' diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and in forced diuresis during and after surgery. Bumetanide may be given orally, intravenously
D C Brater
The American journal of cardiology, 57(2), 20A-25A (1986-01-24)
Bumetanide and furosemide are potent loop diuretics; the former is 40 to 50 times more potent than the latter on a weight basis. Bumetanide is absorbed more quickly than furosemide and is twice as bioavailable. Both drugs exhibit changes in
C E Halstenson et al.
Drug intelligence & clinical pharmacy, 17(11), 786-797 (1983-11-01)
Bumetanide is a recently introduced diuretic that inhibits sodium transport in the thick ascending limb of the loop of Henle. It is structurally and pharmacologically similar to furosemide, but is approximately 40 times as potent on a milligram-for-milligram basis. After
E Petzinger et al.
Journal of hepatology, 24 Suppl 1, 42-46 (1996-01-01)
Bumetanide is a weak organic acid which is transported into hepatocytes by a transport system that is related neither to the cloned sodium-dependent taurocholate cotransporting polypeptide Ntcp nor to the cloned organic anion transporting polypeptide oatp. Bumetanide is known to

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)